Keyword: AstraZeneca

Pascal Soriot’s reign at AstraZeneca is once again rumored to be coming to an end, and the company has reportedly begun looking for his successor.

AstraZeneca spent the last 16 months trying to keep investors’ hopes alive that its Mystic trial could succeed after an initial flop. But it didn’t.

Critics have blasted AstraZeneca’s rummage-sale strategy as unsustainable, but CEO Pascal Soriot says it's vital for bottom-line growth.

The FDA has bestowed its priority review designation on Lynparza, setting it up for a billion-dollar opportunity—and a leg up on its PARP rivals.

With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.

England’s cost-effectiveness watchdogs aren’t convinced AZ and Merck’s PARP drug Lynparza is worth the cost in a bigger group of patients.

Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.

A top pharma CEO says President Trump is right to say other countries benefit from higher U.S. drug prices, but he’s not sold on proposals for a fix.

AZ put skeptics to rest with a long-promised "return to growth." But it’s still far from its $40B sales goal—and its CEO doubled down on it anyway.

A lot has changed in the severe asthma market lately—including the way GlaxoSmithKline is talking about its contender, Nucala.